Title

Phase III randomised double-blind controlled trial of oral risperidone, haloperidol or placebo with rescue subcutaneous midazolam for delirium management in palliative care

RIS ID

101303

Publication Details

Agar, M., Lawlor, P., Quinn, S., Caplan, G., Draper, B., Rowett, D., Devilee, L., Fazekas, B., Sanderson, C., McCaffery, N., Hardy, J., Le, B., Eckermann, S., Hill, M. & Currow, D. (2015). Phase III randomised double-blind controlled trial of oral risperidone, haloperidol or placebo with rescue subcutaneous midazolam for delirium management in palliative care. Australasian Journal on Ageing, 34 (Issue Supplement S1), 33-33.

Abstract

Aims: Guidelines recommend targeted use of antipsychotics in delirium for specific symptoms however this approach has not been evaluated in randomised trials. To compare the efficacy of risperidone relative to placebo in the control of specific delirium symptoms in palliative care patients (communication, behaviour and/or perceptual disturbances on Nursing Delirium Screening Scale) at 72 hours after study commencement. Secondary aims were to compare haloperidol and placebo; and risperidone and haloperidol.

Please refer to publisher version or contact your library.

Share

COinS
 

Link to publisher version (DOI)

http://dx.doi.org/10.1111/ajag.12241